Cidara Therapeutics Inc. (NASDAQ:CDTX) surged over 100% last week, following news of its $9.2 billion acquisition by Merck Co. The stock hit $218.85 before closing at $217.71 on Friday. The deal is expected to close in Q1 2026, after CDTX received FDA fast track designation for its flu prevention drug CD388.

CDTX is currently testing CD388 in a Phase 3 study for at-risk flu patients. While CDTX shows promise, other AI stocks may offer higher returns with less risk. For a potential investment, consider exploring AI stocks in the market. Find out more about potential short-term AI stock opportunities.

Read more at Yahoo Finance: Cidara (CDTX) Climbs 105% on $9.2-Billion Merger with Merck